A retrospective study of outcomes of HT patients who experienced mild to moderate coronavirus disease 2019 (COVID-19), with subsequent administration of casirivimab plus imdevimab administration
Latest Information Update: 10 Jun 2022
At a glance
- Drugs Casirivimab/imdevimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 10 Jun 2022 New trial record
- 30 Apr 2022 Results presented at the 42nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation